Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Nolan

Showing results (1-10 of 104) with videos related to

Pageof 11
Sort By:
Drug Safety|December 7, 2005
Do non-nucleoside reverse transcriptase inhibitors contribute to lipodystrophy?David Nolan
Drugs|November 26, 2003
Metabolic complications associated with HIV protease inhibitor therapyDavid Nolan
Critical Reviews in Clinical Laboratory Sciences|June 12, 2009
HLA-B*5701 screening prior to abacavir prescription: clinical and laboratory aspectsDavid Nolan
Antiviral Therapy|January 18, 2005
Complications associated with NRTI therapy: update on clinical features and possible pathogenic mechanismsDavid Nolan, Simon Mallal
Sexual Health|December 13, 2005
Antiretroviral-therapy-associated lipoatrophy: current status and future directionsDavid Nolan, Simon Mallal
Expert Opinion on Drug Safety|August 9, 2003
4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. San Diego, California, USA 22-25 September 2002David Nolan, Frank Christiansen
Journal of HIV Therapy|July 4, 2003
Thymidine analogue-sparing highly active antiretroviral therapy (HAART)David Nolan, Simon Mallal
Current Opinion in HIV and AIDS|April 18, 2009
Adipose tissue inflammation and altered adipokine and cytokine production in antiretroviral therapy-associated lipodystrophyEmma Hammond, David Nolan
Journal of HIV Therapy|July 9, 2004
The role of nucleoside reverse transcriptase inhibitors in the fat redistribution syndromeDavid Nolan, Simon Mallal
Mitochondrion|August 27, 2005
Potential roles for uncoupling proteins in HIV lipodystrophyDavid Nolan, Craig Pace
Pageof 11

Showing results (1-10 of 104) with videos related to

Sort By:
Pageof 11
Drug Safety|December 7, 2005
Do non-nucleoside reverse transcriptase inhibitors contribute to lipodystrophy?David Nolan
Drugs|November 26, 2003
Metabolic complications associated with HIV protease inhibitor therapyDavid Nolan
Critical Reviews in Clinical Laboratory Sciences|June 12, 2009
HLA-B*5701 screening prior to abacavir prescription: clinical and laboratory aspectsDavid Nolan
Antiviral Therapy|January 18, 2005
Complications associated with NRTI therapy: update on clinical features and possible pathogenic mechanismsDavid Nolan, Simon Mallal
Sexual Health|December 13, 2005
Antiretroviral-therapy-associated lipoatrophy: current status and future directionsDavid Nolan, Simon Mallal
Expert Opinion on Drug Safety|August 9, 2003
4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. San Diego, California, USA 22-25 September 2002David Nolan, Frank Christiansen
Journal of HIV Therapy|July 4, 2003
Thymidine analogue-sparing highly active antiretroviral therapy (HAART)David Nolan, Simon Mallal
Current Opinion in HIV and AIDS|April 18, 2009
Adipose tissue inflammation and altered adipokine and cytokine production in antiretroviral therapy-associated lipodystrophyEmma Hammond, David Nolan
Journal of HIV Therapy|July 9, 2004
The role of nucleoside reverse transcriptase inhibitors in the fat redistribution syndromeDavid Nolan, Simon Mallal
Mitochondrion|August 27, 2005
Potential roles for uncoupling proteins in HIV lipodystrophyDavid Nolan, Craig Pace
Pageof 11